ANCA Associated Vasculitis Clinical Trials

90 clinical trials for ANCA Associated Vasculitis across international registries, including 34 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis — RECRUITING
• BDB-001 Phase III Trial in ANCA-Associated Vasculitis — RECRUITING · PHASE3
• A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. — RECRUITING · PHASE1
• Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders — RECRUITING · PHASE1
• Discontinuation of rituximab compared with rituximab maintenance in ANCA-associated vasculitis – a randomized non-blinded controlled trial (DISRITUX) — RECRUITING · PHASE4
• The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases — RECRUITING · PHASE1
• A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial — RECRUITING · PHASE3
• Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis — RECRUITING
• MTS109 in Patients With Refractory Autoimmune Diseases — RECRUITING · PHASE1
• Biocollection of Patients With ANCA Associated Vasculitis — RECRUITING · NA
• EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases — RECRUITING
• Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA — RECRUITING · PHASE2
• A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease — RECRUITING · PHASE1
• Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases — RECRUITING · PHASE1
• PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis — RECRUITING
• Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases — RECRUITING · PHASE1
• CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases — RECRUITING · PHASE1
• Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases — RECRUITING · NA
• (68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis — RECRUITING
• CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases — RECRUITING · PHASE1
• Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy — RECRUITING
• Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases — RECRUITING · PHASE1
• A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases — RECRUITING · PHASE1
• Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis — RECRUITING · PHASE4
• Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases — RECRUITING · PHASE1
• AYLo - AutoimmunitY and Loss of y — RECRUITING
• BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases — RECRUITING · PHASE2
• Early-access Avacopan in Real-world ANCA-associated Vasculitis — RECRUITING
• Rare AutoImmune SElf-management Programme Development — RECRUITING
• Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis — RECRUITING
• Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells — RECRUITING · NA
• Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM) — RECRUITING · PHASE4
• Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM) — RECRUITING · PHASE4
• Multicenter Cohort Study of AAV in Hunan of China — RECRUITING
• Alemtuzumab for ANCA-Associated Refractory Vasculitis - A study of safety and efficacy (ALEVIATE). — COMPLETED · PHASE4
• Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research — NOT_YET_RECRUITING
• Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis — NOT_YET_RECRUITING · PHASE2
• Predicting future flares and loss of kidney function in inactive ANCA-associated vasculitis patients (The PRE-FLARED 2 Study) — OTHER
• Long-term Outcomes After Avacopan Therapy in ANCA-associated Vasculitis: Relapse Risk After Discontinuation and Subgroup Analysis of Patients With Diffuse Alveolar Hemorrhage (AVA-CLEAR-DAH) — OTHER
• Avacostar - (PASS) — ACTIVE_NOT_RECRUITING
• CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases — NOT_YET_RECRUITING · PHASE1
• Avacopan added to standard-of-care therapy in ANCA-associated vasculitis with severe kidney involvement: a randomized, placebo-controlled, double-blinded multicenter superiority study — COMPLETED · PHASE3
• Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV — WITHDRAWN
• PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS — ACTIVE_NOT_RECRUITING
• PR3-AAV Resilient Remission or PRRR — TERMINATED · PHASE2
• Hydroxychloroquine in ANCA Vasculitis Evaluation — TERMINATED · PHASE4
• Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis. — NOT_YET_RECRUITING · PHASE4
• YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases — NOT_YET_RECRUITING · PHASE1
• CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 — ACTIVE_NOT_RECRUITING · PHASE1
• Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases — SUSPENDED · PHASE1

Refine this search